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Abstract
Background: Our objective was to explore the impact of a single dose of an aromatase inhibitor (letrozole)
administered at defined times of the follicular phase or immediately after ovulation on dominant follicle
development, luteogenesis and new follicle wave emergence.
Methods: A prospective pilot study using a randomized complete block, controlled, open label design was
conducted at an academic clinical research center. Forty-five healthy, female volunteers (25.5 ± 0.9 years, BMI 25.0 ±
0.6 kg/m2) who had not taken hormonal contraceptives for a minimum of 2 months were recruited. A 20 mg dose
of Letrozole was administered once orally in each of 3 groups when the dominant follicle reached a diameter of 1)
12 mm, 2) 18 mm, 3) the first day following ovulation (post-ovulation), or 4) treatment was withheld (control). Serial
ultrasonography and phlebotomy began on day 4 of the menstrual cycle and continued for 1.5 menstrual cycles.
Participants recorded menses and daily events in a life events calendar for the duration of the study. Demographic
and single point measurements were compared among groups by ANOVA. Changes in hormone concentrations
over time were compared among groups by repeated measures ANOVA. Kruskal-Wallis tests were used for non-
normally distributed data.
Results: The dominant follicle in all treatment groups ovulated. There were no differences among experimental
groups in peak follicle diameter, follicular growth rate, endometrial thickness at ovulation or inter-ovulatory interval.
Plasma concentrations of estradiol dropped, while FSH and LH concentrations rose following treatment in all
treatment groups. Plasma FSH and LH concentrations were higher in the 18 mm group compared to the 12 mm
and post-ovulation groups (P < 0.02).
Conclusion: Administration of a single 20 mg dose of Letrozole at the times of the menstrual cycle we examined
did not induce dominant follicle regression or failure of corpus luteum formation. Letrozole-induced suppression of
estradiol synthesis by the dominant follicle was not detrimental to follicle growth or ovulation following follicle
selection, likely due to increased circulating concentrations of FSH and LH resulting from a lack of estradiol-induced
suppression of the hypothalamic-pituitary-ovarian axis.
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Background
The traditional model of folliculogenesis during the hu-
man menstrual cycle posits that a single cohort of antral
follicles in the ovary begins to grow at the beginning of
the menstrual cycle and a dominant follicle is physiolo-
gically selected in the mid-follicular phase: ovulation of
the dominant follicle occurs approximately 2 weeks fol-
lowing the onset of menses [1]. However, a more current
model has evolved through the use of serial transvaginal
ultrasonography which enabled detailed characterization
of follicular and luteal dynamics through the identifica-
tion of definitive ovarian points of reference; i.e., the oc-
currence of ovulation and the emergence of follicular
waves [2–4]. Menses occurs in the middle of the inter-
ovulatory interval and the final of 2 or 3 waves of follicle
development culminates in ovulation. Descriptions of
antral follicle waves in women are consistent with fol-
licular wave dynamics observed during the estrus cycles
of several domestic animal species [5–8].
Data from Canada and the United States emphasize
the need for a better understanding of the regulation of
ovarian function [9–15], as the use of emergency and
cyclic hormonal contraception increases. In 2006, ap-
proximately 450,000 pregnancies were documented in
Canada and 20% ended in elective termination [10, 11].
Similarly, 51% of the 6.7 million documented pregnan-
cies in the United States in 2008 were unintended [13,
14], with 40% of unintended pregnancies ending in
elective termination (20% of all pregnancies) [14]. The
Centers for Disease Control reported 11% of 15–44 year
olds and 23% of 20–24 year olds had ever used an
emergency contraceptive [12]. The reasons for use were
fear of contraceptive failure (45%) and unprotected sex
(49%) [12]. Croxatto et al. [16, 17] have demonstrated
the occurrence of ovulation following emergency
contraception administration varied depending on the
size of the follicle at administration. The closer the
follicle size was to preovulatory, the less likely treat-
ment with a full or half dose of emergency contracep-
tion was going to prevent ovulation [16, 17]. Thus, the
mechanism of action for combined hormonal contra-
ception use as an emergency contraceptive is not well
understood and investigations into the removal of
endogenous estrogen would provide a unique oppor-
tunity to evaluate mechanisms of steroidogenesis im-
pact on folliculogenesis.
The non-steroidal aromatase inhibitor (AI) Letrozole
(FemaraTM) reversibly inactivates the aromatase enzyme
[18–20] and prevents the enzymatic conversion of
androgens to estrogens [19, 21]. Letrozole is the most
commonly used AI for ovulation induction and has been
used successfully when administered between days 3 and
7 of the follicular phase as small 5-day dose (2.5 or
5.0 mg/day) and large single dose (20 mg) regimens [18,
19, 22–24]. To date, there are no reports of AI use initi-
ated at other points of follicle growth in humans.
The decline in FSH coupled with the rise in estradiol
(E2) early in the follicular phase is well documented;
however, the response of post-deviation follicles to de-
creasing E2 and increasing FSH is not well documented
[25, 26]. In the bovine model of ovarian function, neither
a single nor 3 day AI dosing protocol was able to induce
regression of a dominant follicle nor cause an increase
FSH release [27, 28]. Yapura et al. [27, 28] observed a
lengthened follicular dominance and increased secretion
of luteinizing hormone (LH) with a single and 3 day AI
dosing protocol. Single and multi-day dosing in humans
and animal models demonstrated similar results, therefore
the use of the single day protocol should be viewed as
most appropriate [22–24, 27, 28]. A better understanding
of the role of estrogen in controlling folliculogenesis, and
the effects of aromatase inhibitors on post-deviation ovar-
ian function may lead to the development of better proto-
cols for both fertility and contraception. Thus, the overall
objectives of the present study were to evaluate mechanis-
tically the ovarian and endocrine effects of Letrozole treat-
ment when administered at the time of dominant follicle
selection, the immediate pre-ovulatory period and imme-
diate post-ovulatory period during natural menstrual
cycles.
Methods
A prospective pilot study was conducted using a con-
trolled, randomized complete block, open label design at
a single center.
Participants
Forty-five women between the ages of 18 and 35 years
(25.5 years ± 0.9; mean ± SD) with a body mass index
(BMI) of 18–32 (25.0 ± 0.6) were enrolled and 41 women
completed the study. Informed consent was obtained
from all women prior to the initiation of study proce-
dures. All participants were self-reported non-smoking,
healthy women with regular menstrual cycles with no
contraindication to contraceptive or aromatase inhibitor
use (as determined by medical history and physical
examination). The women were naïve to the use of hor-
monal contraceptive or were required to discontinue use
of hormonal contraceptives ≥ 2 months before the study.
Participants were asked to abstain from intercourse during
the study; however, participants were also provided with
barrier contraceptives (condoms) throughout the study to
prevent pregnancy if they were requested.
Treatments
At the time of the first ultrasound examination, women
were assigned to 1 of 4 experimental groups in a ran-
domized, complete block design using a random number
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generator by HCMA. Women in the respective groups
were given a single 20 mg oral dose of letrozole (Femara,
Novartis Pharmaceuticals Canada, Inc., Dorval, Quebec)
when the largest ovarian follicle after menses was first
detected at a diameter of 1) 12 mm (n = 10; peri-
selection group), 2) 18 mm (n = 10; pre-ovulatory
group), or 3) within 24 h after ovulation (n = 10; post-
ovulation group), or 4) were given no treatment (n = 11;
control group).
Ultrasonography
Ovarian follicular and endometrial development were
evaluated by transvaginal ultrasonography using a 6–
9 MHz convex-array transducer (Ultrasonix RP, Vancou-
ver, BC, Canada). Most examinations (95%) were per-
formed by one operator (HCMA); the remaining
examinations were performed by co-authors. Partici-
pants were monitored for 1.5 menstrual cycles (i.e., from
the first menses of the observational period to the first
ovulation after the second menses). Beginning on day 4
(day 1 = first day of menses), ultrasonographic examina-
tions were performed every-other-day until the day of
letrozole treatment in the peri-selection (12 mm) group
or until the dominant follicle was ≥ 16 mm in diameter
in all other experimental groups when ultrasound exam-
inations were done daily thereafter for a minimum of
11 days or until the fate of the dominant follicle was de-
termined (i.e., regression, formation of an anovulatory
follicular cyst, hemorrhagic anovulatory follicle (HAF),
luteinized unruptured follicle (LUF) or ovulation (OV)).
Following ovulation, women in the control group were
then examined every-other-day until the post-treatment
ovulatory follicle attained a 16 mm diameter. Daily ex-
aminations then resumed until the subsequent ovulation.
In all treatment groups, subsequent ultrasound examina-
tions were conducted every-other-day from the time that
the dominant follicle’s fate was determined until the
post-treatment ovulatory follicle was ≥ 16 mm in diam-
eter; daily examinations then resumed until the subse-
quent ovulation. A schematic representation of the study
protocol is shown in Fig. 1.
The number and diameter of antral ovarian follicles ≥
2 mm were imaged and tabulated during each ultra-
sound examination to assess the day of wave emergence.
The average of two orthogonal measurements was used
as the mean follicle diameter for all follicles > 10 mm.
The dominant follicle was defined as the follicle ≥
10 mm that surpassed the diameter of all other follicles
in the cohort by ≥ 2 mm in diameter [2, 3]. Subordinate
follicles were defined as all other follicles in the cohort
with the dominant follicle and the 1st subordinate follicle
was the largest of the subordinate follicles. Co-dominant
follicles were defined as two follicles reaching > 13 mm
[29]. Ovulation was defined as the disappearance of a
follicle ≥ 12 mm in diameter detected ultrasonographically
the previous day, followed by subsequent visualization of a
corpus luteum [30]. Wave emergence was defined retro-
spectively as the day when the largest follicle of each wave
was first identified at 4–5 mm. The identity and non-
identity methods were used to characterize changes in fol-
licle diameter during the study [2, 7, 31]. The diameter
profiles of individual follicles that grew ≥ 8 mm over time
for each woman were tabulated using the day of follicular
wave emergence as the point of reference [2].
Endometrial thickness and pattern also were recorded
during each ultrasound examination following standard
operating procedures of the WHIRL, as previously
described [32]. Briefly, endometrial thickness was mea-
sured as the distance from the anterior stratum basalis-
myometrial junction to the posterior stratum basalis-
myometrial junction in the mid-sagittal plane. The
transverse and sagittal planes of section which repre-
sented the largest dimensions of the fundal aspect of the
endometrium were used for all measurements. Endomet-
rial echotexture pattern was assessed each day as either
an M, A, B, C or D pattern.
Blood sampling
In the treatment groups blood samples were taken daily
for 5 days beginning on the day of treatment. The inter-
val was defined as the observation interval. If the fate of
the extant dominant follicle was not determined after
5 days, blood samples were taken every-other-day until
the dominant follicle met one of the defined fates. In all
Fig. 1 Schematic diagram of the study protocol
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participants a single blood sample was taken 5–9 days
after the fate of the follicle was known. A final blood
sample was taken when the pre-ovulatory follicle of the
second cycle reached 18 mm. In the control group,
blood samples were taken at times equivalent to the day
of treatment in the other groups (i.e., 12 mm follicle,
18 mm follicle, and 24 h post-ovulation), 5–9 days fol-
lowing ovulation and when the pre-ovulatory follicle
reached 18 mm. Blood samples were collected in 7 mL
tubes and allowed to coagulate for 30–45 min at room
temperature before centrifugation for 30 min at 700 × g.
Serum samples were stored at −20 °C until all partici-
pants completed the study.
Daily events charts
All volunteers were provided with an event diary to record
menstrual patterns, concomitant medications and any
adverse events that occurred during the study.
Hormone assays
Competitive fluorescence immunoassays (ImmuliteTM,
Siemens Healthcare Diagnostics Inc., Tarrytown, NY,
USA) were used to measure serum FSH and LH concen-
trations and validated radioimmunoassays were used to
measure serum E2 and progesterone (P4) concentrations.
All assays were performed in a single batch and con-
ducted at Prairie Diagnostic Services at the University of
Saskatchewan. Minimum detectible limits were: FSH: 0.1
mIU/mL; LH: 0.1 mIU/mL; E2: 1.4 pg/mL; and P4:
0.02 ng/mL. Intra-assay coefficients of variation for low,
medium and high reference concentrations, respectively,
were 3.0, 2.9 and 1.6% for FSH, 2.6, 2.4 and 1.6% for LH,
and 3.9, 6.3 and 7.6% for P4. Intra-assay coefficients of
variation for low and high reference concentrations, re-
spectively, were 2.4 and 10.9% for E2. Inter-assay coeffi-
cients of variation were 4.7 and 13.2% (low, high) for E2
and 3.9, 6.3 and 7.6 (low, medium, high) for P4. The
magnitude of the decrease in plasma estradiol concen-
tration following treatment was calculated using the
equation ([E2 day of treatment] – [E2 day of nadir])/(day
of nadir – day 1).
Statistical analyses
Sample size was determined by the mechanistic and
pilot study nature of the trial. All analyses were based on
intent-to-treat. Statistical analyses were performed using
SAS version 9.2 (SAS Institute, Cary, NC, USA). Single-
point measurements were compared among groups by
analysis of variance. Changes in hormone concentrations
(E2, FSH and LH) and endometrial thickness over time
were compared among groups by analysis of variance for
repeated measures (PROC MIXED). Endometrial pat-
terns and intervals from treatment to ovulation were
compared using Kruskal-Wallis tests. Significance was
set at P < 0.05. Results are expressed as the mean ± SEM.
Results
The flow of participants through the study protocol is
shown (Fig. 2). Participants who had aberrations in luteal
follicle wave dynamics were followed ultrasonographi-
cally over a longer time and had extra days of blood
sampling (data not shown). The age and BMI of partici-
pants were similar among treatment groups (Table 1;
P > 0.4). No adverse events were observed in our sub-
jects. Forty-one participants completed the pilot study.
Four participants were excluded or withdrew from the
study prior to receiving treatment and were not included
in the analyses. One participant in the 18 mm group and
one in the control group were lost to follow-up just
prior to ovulation at the end of the study and is included
in all analyses. One participant in the control group ovu-
lated at a small follicle diameter (>14 mm), which was
not observed by ultrasound within 24 h, thus this par-
ticipant was excluded from analyses of hormone data.
Follicular and luteal dynamics
The mean diameter profiles of the dominant and first
subordinate follicles of the ovulatory wave for each treat-
ment group are shown (Fig. 3). The dominant follicles
extant at the time of treatment in all study groups ovu-
lated. Ovulation was confirmed by ultrasonographic ob-
servation of a corpus luteum and a subsequent rise in P4
on days 5–9 [33]. In the 12 mm group, 3 of 10 (30%)
women developed co-dominant follicles: one follicle
ovulated and the other regressed in one woman and
both follicles ovulated in 2 women. One of the 10 (10%)
women in the 18 mm group developed co-dominant
follicles; one follicle ovulated and the other regressed. In
the control group, one of the 11 women (9%) developed
co-dominant follicles; one follicle ovulated at 13 mm
and the other developed into a HAF. Data from this
participant were excluded from hormonal analysis.
The interval from treatment to ovulation differed
among groups (P < 0.0001; Table 2). Peak follicle diam-
eter was greater in the 12 mm group than that of the
18 mm and control groups (P < 0.04). The interval from
treatment to ovulation was longest in the 12 mm group
and shortest in the 18 mm group. There were no differ-
ences among study groups in the rate of growth of the
dominant follicle from treatment to ovulation, or to peak
follicle diameter before follicle rupture was observed in
the post-ovulation group. (P > 0.1; Table 2).
The interval from detection of an 18 mm follicle to
ovulation was shorter in the 18 mm treatment group
than in the control group (41.8 ± 13.1 h vs. 72.5 ±
34.9 h, respectively; P = 0.006). The 12 mm, 18 mm,
post ovulation and control groups had similar
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intervals from ovulation to new follicular wave emer-
gence (0.4 ± 4.5 d, −0.2 ± 2.5 d, 0.5 ± 3.0 d, 0.8 ± 3.2 d,
respectively; P = 0.925).
Day 5–9 serum P4 concentrations were 22.9 ± 5.5 ng/
mL, 16.3 ± 1.8 ng/mL, 13.0 ± 1.4 ng/mL and 24.1 ± 5.7 ng/
mL in the 12 mm, 18 mm, post-ovulation and control
groups, respectively (P = 0.1899) and were above the clin-
ically defined minimum P4 concentration required to con-
firm ovulation. No differences were observed among
groups with regard to P4 concentrations, inter-menstrual
interval and inter-ovulatory interval.
Circulating hormone concentrations
Changes in serum concentrations of E2, FSH and LH in the
treatment groups are shown (Fig. 4). The pattern of change
in serum E2 concentration across the observation interval
differed among the 3 treatment groups (P < 0.0001; Fig. 4a).
The 18 mm group exhibited higher (P < 0.0001) E2 concen-
trations on the day of treatment, which was attributed to
the presence of a pre-ovulatory dominant follicle. Following
treatment E2 concentrations decreased in all treatment
groups (P = 0.0004). The 18 mm group E2 concentrations
reached baseline on the third day after treatment and
remained at baseline until the 5th day (P = 0.8563). The
12 mm group E2 concentrations increased (P = 0.01) from 2
to day 5. The magnitude of the initial drop in E2 concentra-
tion in the 18 mm group was larger than in both the
12 mm and post ovulation groups (P = 0.04).
Fig. 2 Flow of participants through the study from enrollment to data analysis
Table 1 Descriptive Statistics for age and BMI (mean ± SEM) of
participants
Experimental Group N Age (years) BMI (kg/m2)
12 mm 10 24.8 ± 1.9 25.4 ± 0.8
18 mm 10 28.0 ± 1.6 24.5 ± 1.1
Post OV 10 24.0 ± 1.6 24.8 ± 1.4
Control 11 25.2 ± 1.8 25.4 ± 1.1
P-value 0.404 0.934
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Fig. 3 Mean follicle diameter profiles of the treatment groups. The 12 mm group (n = 10; a), 18 mm group (n = 10; b), post-OV group (n = 10; c),
and control group (n = 11; d) are shown separately. Data are shown for 9 days following ovulation and are centralized to the day of treatment for
each respective treatment group or day of OV in the control group
Table 2 Mean follicular end points (mean ± SEM) among experimental groups
Experimental Group N Day of treatment (d) Peak diameter (mm) Follicular growth
rate (mm/d)
Interval from
treatment to OV (d)
12 mm 10 9.2 ± 0.4 23.2 ± 1.0 1.5 ± 0.1 7.4 ± 0.6
18 mm 10 14.5 ± 1.1a 19.8 ± 0.6 1.3 ± 0.1 1.9 ± 0.2a
Post OV 10 17.9 ± 0.8a, b 20.7 ± 1.3 1.5 ± 0.1 −1.0 ± 0.0a, b
Control 11 NA 19.8 ± 1.4 1.2 ± 0.1 NA
P-value 0.0001 0.1266 0.1809 0.0001
All comparisons are within columns
adifference from 12 mm group (P < 0.05)
bdifference from 18 mm group (P < 0.05)
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Plasma FSH concentrations increased and subsequently
decreased to pretreatment concentrations over the 5-day
observation interval in all treatment groups (P = 0.0014;
Fig. 4b). The statistical interaction was attributed to the
immediate FSH increase from day 1 to 2 in the 12 and
18 mm groups (P < 0.0001).
Following treatment, plasma LH concentrations in all
treatment groups initially increased (P = 0.0013; Fig. 4c)
and then decreased to pretreatment levels by the end of
the observation interval. The mean plasma LH concen-
trations over the observation interval were higher in the
18 mm group versus the 12 mm and post ovulation
groups (P < 0.02).
The maximum concentrations of FSH and LH following
treatment differed among treatment groups (P < 0.03).
The 18 mm group had higher FSH and LH concentrations
than the 12 mm and post ovulation groups (P < 0.05);
maximum FSH and LH concentrations did not differ
between the 12 mm and post ovulation groups (P > 0.26).
Endometrial dynamics
Changes in mean endometrial thickness beginning at the
time of pre-treatment menses are shown (Fig. 5). Mean
cycle endometrial thickness and endometrial thickness
and pattern at ovulation were not different among experi-
mental groups (P = 0.1124). There were no differences in
Fig. 4 Change in estradiol, FSH and LH over the observation interval. a Mean changes in E2 concentration over the observation interval in the
treatment groups (day 1 = day of treatment). b Mean changes in FSH concentration over the observation interval (day 1 = day of treatment) in
the treatment groups. c Mean changes in LH concentration over the observation interval (day 1 = day of treatment) in the treatment groups.
Differences among treatment groups are identified within days (P < 0.05). * Within day comparisons among experimental groups. N = 10 for
12 mm, 18 mm and post-OV groups
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the interval from menses to ovulation, inter-ovulatory
interval or inter-menstrual interval among experimental
groups (P = 0.2; Table 3).
Discussion
The dominant follicle observed in all treatment groups
ovulated and there were no differences among experi-
mental groups for peak follicle diameter, follicular
growth rate, nor endometrial thickness at ovulation. As
expected E2 concentration declined, while both FSH and
LH concentrations increased following administration of a
single 20 mg dose of AI in all treatment groups. Differ-
ences among groups in P4 concentrations, inter-menstrual
interval and inter-ovulatory interval were not observed,
therefore, we concluded that there was no effect of
treatment on luteogenesis.
Concentrations of serum E2, FSH and LH on the day
before receiving treatment in each group did not exceed
previously published ranges for the specified physiologic
time points in our laboratory [3] nor did they differ from
the control group at the same time point. Decreased E2
was observed within 24 h of AI administration in all
women, supporting our hypotheses that treatment with
an AI would cause a transient drop in E2. These findings
contrast studies in the bovine model, where increasing
plasma E2 concentrations were observed for 4 days fol-
lowing AI administration in metestrous. The E2 increase
was associated with a simultaneous increase in follicle
diameter [28], which is similar to the continued follicle
development in all our treatment groups despite the
drop in E2 concentrations. In the 12 mm group an in-
crease in E2 concentrations began 2 days after AI admin-
istration and was attributed to the health and continued
growth of the pre-ovulatory dominant follicle, while the
absence of a rise in E2 in the 18 mm and post-ovulation
groups has been attributed to the physiologic drop in E2
secretion following ovulation [3]. A compensatory
mechanism for the preservation of follicle growth and
ovulation following the acute drop in E2 after AI admin-
istration may be explained by the observation of in-
creases in FSH and LH concentrations.
All treatment groups exhibited a rise in FSH following
treatment in the present study. Garcia-Velasco et al. [34]
demonstrated a 7 day delay in a rise in FSH when Letro-
zole was administered during the luteal phase. Both doc-
umented rises in luteal FSH concentrations in women
contrast with a lack of FSH change in the bovine model
[27, 28]. In the present study, all three groups exhibited
a typical mid follicular phase rise in FSH during the
4 days immediately following treatment. A 4-day rise in
FSH following aromatase inhibitor treatment later in the
follicular phase (day 12 and 18) appeared to elongate the
FSH rise thus potentially allowing multiple dominant
follicles to develop.
Circulating LH concentrations reached maximum
concentrations within 24 h of treatment and returned to
initial concentrations by the end of the observation
interval in all groups. The rise in LH concentrations
within 24 h is consistent with reports of AI treatment in
the bovine model [27, 28]. A sustained elevation in LH
following cessation of follicular phase AI administration has
not previously been reported in women [18, 20, 22–24].
Bedaiwy et al. [35] documented no difference in LH
Fig. 5 Mean profiles of endometrial thickness. Women in all
treatment groups, 12 mm (n = 10), 18 mm (n = 10), 24 h post
ovulation (n = 10), and control (n = 11) are identified. Data are shown
for one inter-menstrual interval and are centralized to the day of
ovulation. No significant effect of day was observed for
endometrial thickness
Table 3 Descriptive statistics for physiologically relevant intervals (mean ± SEM) among experimental groups









12 mm 10 16.6 ± 0.5 27.6 ± 1.1 29.5 ± 1.6 19.7 ± 1.3
18 mm 10 16.4 ± 1.1 29.6 ± 1.4 26.9 ± 2.0 16.1 ± 0.6a
Post OV 10 16.9 ± 0.8 28.0 ± 1.0 23.9 ± 3.0 11.1 ± 0.9a, b
Control 11 17.2 ± 1.0 28.5 ± 1.1 29.0 ± 1.1 NA
P-value 0.9284 0.6551 0.2014 0.0001
All intervals are in days
N = 9 for 18 mm group and N = 10 for control group in inter-ovulatory interval column
adifference from 12 mm group (P < 0.05)
bdifference from 18 mm group (P < 0.05)
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concentrations in AI treated cycles compared to natural
cycles up to day 11 of the menstrual cycle; however, treat-
ment with 2.5 mg AI led to significantly lower LH on the
day of hCG administration. It has been suggested that the
prolonged elevation in LH following aromatase inhibitor
treatment in the follicular and luteal phases indirectly en-
hances dominant follicle development [27, 28].
When treatment was administered at a 12 mm follicle
diameter the selected follicle continued to grow, and
attained a larger pre-ovulatory size compared with the
18 mm treatment group and control group and there
was a tendency for the follicle to be larger than observed
in the post-ovulation group. However, in the 18 mm
group there was no change in follicle diameter at ovula-
tion compared to the control group. The trend towards
a larger ovulatory follicle in the 12 mm group may be re-
lated to the acute drop in E2 in the mid-follicular phase.
We postulated that the compensatory rise in FSH and
LH following an AI induced drop in E2 accentuated fol-
licular growth. However, within the constraints imposed
by our study design, we were unable to conclude that AI
treatment affects ovulatory follicle diameter.
Our observation of an unaltered growth profile is in
contrast with the bovine model where a single, large dose
of letrozole after follicle selection prolonged the interval
from treatment to ovulation [27, 28]. To date, there has
been no in depth evaluation of the effects of AI use on fol-
licle growth profiles when administered prior to dominant
follicle selection (i.e., 10 mm diameter). In retrospect, it
would have been useful to have include a treatment group
in which women received Letrozole on the 3rd day follow-
ing menses an prior to follicle selection. Initiation of AI
treatment prior to selection has been documented in ovu-
lation induction, which appears to release negative feed-
back on FSH secretion and stimulate further growth of
the extant follicular wave; however, available studies did
not measure changes in FSH during treatment [19, 20, 22,
24, 35]. In natural menstrual cycles, the duration of the
FSH rise at wave emergence is short and it is presumed
that this is due to the negative feedback system of E2 and
inhibin B. This mechanism is postulated to ensure mono-
vulation [20].
In the present study, multiple dominant follicles were
developed by women in the 12 mm, 18 mm and control
groups in the follicular phase of the treatment cycle. In
the 12 mm group, 20% of the women ovulated two folli-
cles during the treatment period, in contrast with the re-
ported 4% natural occurrence of double ovulation [26, 29].
Another participant in the 12 mm group developed a sec-
ond dominant follicle that regressed. This observation is
conceptually similar to a recent study in the bovine model
wherein the 1st subordinate follicle of animals given an AI
in the follicular growth phase (day 1–3) exhibited larger
mean diameters [27]. It was postulated that an extended
mid follicular phase FSH rise in women allowed a subor-
dinate follicle to be rescued from atresia. In both the
18 mm and control groups, a second dominant follicle
grew but either regressed (10%) or resulted in ovulatory
failure (9%). Ovulatory failure occurs in approximately 5%
of cycles of regularly cycling women [36] and 10% of cy-
cles in infertile women [37, 38]. An increased incidence of
ovulatory failure was not observed in the present study.
We were limited in our ability to evaluate the impact of
AI treatment on luteal function. We hypothesized that AI
treatment would result in ovulatory failure and hence did
not anticipate a need for the evaluation of serial luteal
phase P4. We were also limited in our ability to directly as-
sess differences between the control group in this pilot
study and each of the treatment groups across the entire
treatment timeframe. Blood draws in the control group
were timed only to coincide with the times of letrozole
treatment. An optimal design to facilitate comparison of
the control group to the treatment groups during the
observation interval would have required volunteers to
submit to daily blood collection for approximately 15 con-
secutive days. We were already limited by our ability to at-
tract volunteers for the study protocol as executed. We
were also financially unable to support a separate control
group in this study for each treatment group.
Conclusions
Aromatase inhibitor treatment at follicle diameters of
12 mm or 18 mm or 24 h post ovulation were associated
with a transient decrease in E2 concentrations and ele-
vated circulating FSH and LH concentrations during the
4 days following treatment. The drop in E2 concentration
did not suppress dominant follicle growth or early corpus
luteum development. These results were unexpected
and provide an impetus for additional studies to elu-
cidate the roles of E2, LH and FSH in the regulation
of follicle and luteal development in women. There is
no reason to suspect other commercially available
aromatase inhibitors (i.e., anastrozole) would have
different effect than the observations made with letro-
zole on ovarian function.
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